Beam Therapeutics (BEAM) just crossed a major clinical hurdle. The firm reported that its sickle cell therapy candidate, ristoglogene autogetemcel, met all primary and secondary endpoints in the BEACON Phase 1/2 trial. Beam Therapeutics has not seen that clinical success translate into short term share price strength, with the stock down 6.9% on a 1 day basis and weaker over the past week, month and quarter. However, the 1 year total shareholder return of 11.9% and 3 year total shareholder...
2026-10-29. The following slide deck was published by Beam Therapeutics Inc.
Tipranks Press Release.
Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.
Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.
Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology co
Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.
In September 2026, Beam Therapeutics filed a lawsuit alleging that former scientist Zi Jun “Emma” Wang stole confidential research to co-found Chinese biotech YolTech Therapeutics and, through it, helped create Serapha Bio using Beam’s trade secrets and patentable know‑how. This dispute underscores intensifying concerns over intellectual property protection and cross‑border competition in gene editing, particularly between U.S. and Chinese biotech companies. We’ll now examine how this...
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028–2029, cash runway/dilution risks, valuation vs peers—read now.
Beam Therapeutics sits in a crowded gene editing field, and its share price history raises a simple question for you as an investor: Is the current US$24.37 price properly reflecting what the business is generating in sales today? Over the past 5 years the stock has fallen 72.1%, which puts the focus squarely on whether the revenue it produces can still justify even the current market value. Recent coverage of the in vivo gene editing market highlights Beam Therapeutics as a key participant...
Beam Therapeutics Inc. (NASDAQ:BEAM) reported updated Phase 1/2 results on September 8 for BEAM-302, an investigational gene-editing treatment for alpha-1 antitrypsin deficiency, or AATD. Although 38 patients had been treated by August 17, the presented efficacy analysis covered 29 single-dose patients at the June 24 cutoff. Biomarker results extended to 18 months, while overall patient […]
Beam Therapeutics (BEAM) stock slips on updated data from a Phase 1/2 trial for BEAM-302, its gene-editing drug for alpha-1 antitrypsin deficiency. Read more here.
Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease. The company shared these findings at the European Respiratory Society Congress 2026, showcasing the genetic medicine’s potential to directly correct the root cause of both liver and
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corres
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. “Eric is an exceptional biopharmaceutical leader w
Beam Therapeutics has delivered a sharp 86.5% share price gain over the past year, yet the stock screens as expensive on broader valuation checks, which leaves recent buyers paying up for its gene editing potential without clear support from traditional metrics. The 86.5% 1 year return highlights how strongly sentiment has swung in favor of Beam Therapeutics, even though the business is still early in its commercial journey. Expectations that Beam Therapeutics can eventually turn its gene...
This is the newest page. Registered accounts read further back.